gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Solute carrier family 6

DAT1, Dopamine transporter, SLC6A3
This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.[provided by RefSeq, Nov 2009] (from NCBI)
Top mentioned proteins: DRD4, HAD, AGE, DRD2, CAN
Papers on DAT1
Rapid eye movement sleep behaviour disorder symptomatic of a brain stem cavernoma.
New
Peter-Derex et al., Bron, France. In J Sleep Res, Feb 2016
Dopamine transporter imaging [123I-FP-CIT single photon emission computed tomography (SPECT)] did not find any presynaptic dopaminergic pathways degeneration.
Gene-Environment Correlation Between the Dopamine Transporter Gene (DAT1) Polymorphism and Childhood Experiences of Abuse.
New
Santtila et al., Turku, Finland. In J Interpers Violence, Feb 2016
UNASSIGNED: In the present study, we investigated the possible gene-environment correlation between the dopamine transporter gene (DAT1) polymorphism and childhood experiences of abuse and neglect.
Meta-analysis of the association of the SLC6A3 3'-UTR VNTR with cognition.
Review
New
Kambeitz et al., Bonn, Germany. In Neurosci Biobehav Rev, Jan 2016
The gene coding for the dopamine transporter (DAT), SLC6A3, contains a 40-base pair variable number of tandem repeats (VNTR) polymorphism (rs28363170) in its 3' untranslated region.
[Scans without Evidence of Dopamine Deficit (SWEDDs)].
Review
New
Murata et al., In Brain Nerve, Jan 2016
Dopamine transporter (DaT) single-photon emission computed tomography (SPECT) and[<sup>18</sup>F]fluoro-L-DOPA ([<sup>18</sup>F]DOPA) positron emission tomography (PET) facilitate the investigation of dopaminergic hypofunction in neurodegenerative diseases.
Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.
New
Lin et al., Toronto, Canada. In Schizophr Bull, Jan 2016
UNASSIGNED: SLC6A3, which encodes the primary regulator of extracellular dopamine (DA) concentration, the DA transporter, has been implicated in schizophrenia (SCZ).
Semiquantitative slab view display for visual evaluation of 123I-FP-CIT SPECT.
New
Declerck et al., Berlin, Germany. In Nucl Med Commun, Jan 2016
OBJECTIVE: Dopamine transporter single-photon emission computed tomography (SPECT) with I-FP-CIT is used widely in the diagnosis of clinically uncertain parkinsonian syndromes.
Comparison of Quantitative Value of Dopamine Transporter Scintigraphy Calculated from Different Analytical Software.
New
Kitagaki et al., Japan. In Nihon Hoshasen Gijutsu Gakkai Zasshi, Dec 2015
In the dopamine transporter scintigraphy there are two quantitative analysis softwares, DaTView and DaTQUANT.
Attention deficit hyperactivity disorder: genetic association study in a cohort of Spanish children.
New
Ayuso et al., Madrid, Spain. In Behav Brain Funct, Dec 2015
RESULTS: After correcting for multiple testing, we found several significant associations between the polymorphisms and ADHD (p value corrected ≤0.05): (1) SLC6A4 and LPHN3 were associated in the total population; (2) SLC6A2, SLC6A3, SLC6A4 and LPHN3 were associated in the combined subtype; and (3) LPHN3 was associated in the male sample.
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.
Review
New
Nielsen et al., Houston, United States. In Psychiatr Genet, Oct 2015
Polymorphisms of the DRD2, ANKK1, DAT1, DBH, and DRD4 genes have been found to moderate the effects of pharmacotherapy of alcohol, opioid, and cocaine use disorders.
Progress in the Search for New Dopamine Transporter Inhibitors.
Review
Kulig et al., Kraków, Poland. In Curr Med Chem, 2014
In the present review, we provide a comprehensive summary of recent pharmacological studies on dopamine transporter (DAT) inhibitors, which are potential treatments for neurodegenerative and psychiatric disorders.
Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
Review
Hyde et al., Banbury, United Kingdom. In Cochrane Database Syst Rev, 2014
Dopamine transporter (DAT) imaging using single-photon emission computed tomography (SPECT) is the most highly developed supplementary test for DLB, and is now incorporated as a suggestive feature in the consensus diagnostic criteria.
DRD2/ANKK1 TaqIA and SLC6A3 VNTR polymorphisms in alcohol dependence: association and gene-gene interaction study in a population of Central Italy.
GeneRIF
Ceccanti et al., Italy. In Neurosci Lett, 2012
Our study extends and confirms previous results and, for the first time, tested the gene-gene interaction between SLC6A3 and DRD2 in alcohol dependence.
Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
GeneRIF
Suhara et al., Chiba, Japan. In J Nucl Med, 2012
(18)F-FE-PE2I is a promising PET radioligand for quantifying DAT
Dopamine transporter (DAT1) VNTR polymorphism and alcoholism in two culturally different populations of south India.
GeneRIF
Raghavendra Rao et al., Hyderābād, India. In Am J Addict, 2012
The DAT1 VNTR was significantly associated with alcoholism in Badaga population but not in Kota population of south India.
Serotonin transporter role in identifying similarities between SIDS and idiopathic ALTE.
GeneRIF
Nonnis Marzano et al., Parma, Italy. In Pediatrics, 2012
No association was found between DAT polymorphisms and apparent life-threatening events (ALTE) and idiopathic form (IALTE)groups either at the genotype or allelic level.
Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation.
GeneRIF
Blakely et al., Nashville, United States. In J Neurosci, 2012
The results of thisstudies support a coupling of DAT microdomain localization with transporter regulation and provide evidence of perturbed DAT activity and DA signaling as a risk determinant for Attention deficit/hyperactivity disorder.
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.
Impact
GeneRIF
Maher et al., Birmingham, United Kingdom. In Lancet Neurol, 2011
Children with mutations in the SLC6A3 childhood, patients developed severe parkinsonism-dystonia associated with an eye movement disorder and pyramidal tract features.
Mechanism of chloride interaction with neurotransmitter:sodium symporters.
Impact
Kanner et al., Jerusalem, Israel. In Nature, 2007
Equivalent mutations introduced in the mouse GABA transporter GAT4 (SLC6A11) and the human dopamine transporter DAT (SLC6A3) also result in chloride-independent transport, whereas the reciprocal mutations in LeuT and Tyt1 render substrate binding and/or uptake by these bacterial NSS chloride dependent.
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Impact
Parkinson Study Group, In Jama, 2002
OBJECTIVE: To compare rates of dopamine neuron degeneration after initial treatment with pramipexole or levodopa in early PD by means of dopamine transporter imaging using single-photon emission computed tomography (SPECT) with 2beta-carboxymethoxy-3beta(4-iodophenyl)tropane (beta-CIT) labeled with iodine 123.
Dopamine transporter density in patients with attention deficit hyperactivity disorder.
Impact
Fischman et al., In Lancet, 2000
Dopamine transporter density was measured in vivo in six adult patients with attention deficit hyperactivity disorder.
share on facebooktweetadd +1mail to friends